Pharmacy & Therapeutics/Drug Utilization Review Committee

October 13, 2026
8:00 AM-12:00 PM

Virtual option:
Microsoft Teams meeting
Join: https://teams.microsoft.com/meet/247269192493726?p=ny1cocB3aMNblwhEvp
Meeting ID: 247 269 192 493 726
Passcode: KR9Rb2Hf

Dial in by phone

+1 505-312-4308,,648936219# United States, Albuquerque

(888) 506-1357,,648936219# United States (Toll-free)

Find a local number

Phone conference ID: 648 936 219#

Agenda Item	Leader
Welcome	K. Ryan
Approval of Agenda (Attachment A)	K. Ryan
Roll Call of P&T Members	K. Ryan
Approval of Minutes from July 29, 2026 (Attachment B)	K. Ryan
State Updates • Turquoise Claims • Provider Enrollment • Discussion of Standard Operating Procedures (SOP)	K. Ryan
Closed Session - PDL Class Review & Voting	K Ryan

• FFS GLP-1 approved for some items, not weight loss - Vote • Conduent 3-year maintenance duration – drug approval -- FYI • Generous - FYI • Gender affirming criteria – can't cover 18 yoa and younger -- FYI • OTC list – FYI	
Break	
Open Session	
Drug Class Review Proposed New Drug Classes • Anticonvulsants • Erythropoiesis-Stimulating Agents New to Market Medications • Antipsychotics • Cytokine and CAM Antagonists • Ophthalmic Anti-inflammatories Established Drug Classes with proposed additions: • Antidepressants – Other • Antihistamines – Minimally Sedating • Antihypertensives – Sympatholytic • Anxiolytics • Bronchodilators, Beta Agonist • Glucocorticoids – Inhaled • Intranaslal Rhinitis Agents • NSAIDS • Ophthalmic Antibiotics • Ophthalmic Antibiotic/Steroid Combinations • Ophthalmic Agents for Allergic Conjunctivitis • Ophthalmic Glaucoma Agents and Related Agents • Otic Antibiotics • Topical Steroids – Very High Potency • Topical Steroids – High Potency Classes with No Proposed Changes: • Antidepressants – SSRIs • Antihyperuricemics • COPD Agents • Epinephrine – Self-Administered • Histamine ll Receptor Blockers • Immunomodulators – Asthma • Immunomodulators – Atopic Dermatitis • Leukotriene Modifiers • Movement Disorders	

• Ophthalmic Dry Eye Agents • Smoking Cessation • Topical Steroids – Low Potency • Topical Steroids – Medium Potency	
HCA Administrative Updates	
Open Comments	Prime/K. Ryan
ProDUR	K. Ryan
RetroDUR	Conduent
Quarterly reports	Conduent
Upcoming Interventions •	Conduent
•	Conduent
Adjournment	K. Ryan